Nature Reviews Drug Discovery

Article	Citations
Engineering precision nanoparticles for drug delivery	3306
Natural products in drug discovery: advances and opportunities	2084
Advances in oligonucleotide drug delivery	1062
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	1026
PROTAC targeted protein degraders: the past is prologue	983
Trends in peptide drug discovery	852
Noncoding RNA therapeutics — challenges and potential solutions	764
Emerging concepts in the science of vaccine adjuvants	641
mRNA vaccines for infectious diseases: principles, delivery and clinical translation	611
RAS-targeted therapies: is the undruggable drugged?	574
Kinase drug discovery 20 years after imatinib: progress and future directions	513
Macrophages as tools and targets in cancer therapy	502
Targeting inflammation in atherosclerosis — from experimental insights to the clinic	473
Organs-on-chips: into the next decade	464
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing	450
Evolution of the COVID-19 vaccine development landscape	437
Strategies for delivering therapeutics across the blood–brain barrier	435
Targeting cancer metabolism in the era of precision oncology	407
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine	404
Radiopharmaceutical therapy in cancer: clinical advances and challenges	388
Anti-obesity drug discovery: advances and challenges	376
Trends in kinase drug discovery: targets, indications and inhibitor design	350
Channelling inflammation: gasdermins in physiology and disease	343
Antisense technology: an overview and prospectus	311
B cell depletion therapies in autoimmune disease: advances and mechanistic insights	309

FDA approves 100th monoclonal antibody product	298
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics	288
The clinical landscape for AAV gene therapies	285
Poly(ADP-ribose) polymerase inhibition: past, present and future	282
Therapeutically harnessing extracellular vesicles	278
Targeting the epigenetic regulation of antitumour immunity	275
The quest to slow ageing through drug discovery	261
Navigating CAR-T cells through the solid-tumour microenvironment	248
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease	245
Targeted protein degraders crowd into the clinic	241
Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target	234
PI3K inhibitors are finally coming of age	232
Base editing: advances and therapeutic opportunities	229
Kinase inhibition in autoimmunity and inflammation	228
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans	226
Beyond immune checkpoint blockade: emerging immunological strategies	218
Advances in covalent drug discovery	214
Advances in TRP channel drug discovery: from target validation to clinical studies	212
The foundations of immune checkpoint blockade and the ipilimumab approval decennial	211
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials	208
Image-based profiling for drug discovery: due for a machine-learning upgrade?	202
Emerging therapeutic opportunities for integrin inhibitors	199
Protein arginine methylation: from enigmatic functions to therapeutic targeting	192
Identification of neoantigens for individualized therapeutic cancer vaccines	188
Pharmacological targeting of endoplasmic reticulum stress in disease	180
Circadian rhythm as a therapeutic target	178
Drugging p53 in cancer: one protein, many targets	173
Function and therapeutic value of astrocytes in neurological diseases	173
Targeting HER2-positive breast cancer: advances and future directions	170
Targeting RNA structures with small molecules	167
Therapeutic strategies targeting FOXO transcription factors	166
Advances in targeting ‘undruggable’ transcription factors with small molecules	163
Antitumour dendritic cell vaccination in a priming and boosting approach	151
Targeting Notch in oncology: the path forward	146
Engineering living therapeutics with synthetic biology	145
Therapeutic strategies for COVID-19: progress and lessons learned	143
2020 FDA drug approvals	141
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities	141
Lipogenesis inhibitors: therapeutic opportunities and challenges	132
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies	123
The PROTACtable genome	119
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease	119
The emerging role of mass spectrometry-based proteomics in drug discovery	118
Targeting co-stimulatory molecules in autoimmune disease	110
Engineering the next generation of cell-based therapeutics	108
Exosome-based candidates move into the clinic	104
Drugging the efferocytosis process: concepts and opportunities	101
Modulating biomolecular condensates: a novel approach to drug discovery	99
Antibody–drug conjugates come of age in oncology	98
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape	98

Impact of COVID-19 on oncology clinical trials	97
Immune targets for therapeutic development in depression: towards precision medicine	97
Combinations take centre stage in PD1/PDL1 inhibitor clinical trials	96
The glomerular filtration barrier: a structural target for novel kidney therapies	93
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation	92
Targeting replication stress in cancer therapy	92
A tale of two antiviral targets — and the COVID-19 drugs that bind them	91
Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs	87
Improving target assessment in biomedical research: the GOT-IT recommendations	86
Phenotypic drug discovery: recent successes, lessons learned and new directions	86
The promises and perils of psychedelic pharmacology for psychiatry	86
Rational combinations of targeted cancer therapies: background, advances and challenges	83
2021 FDA approvals	78
Antibodies to combat viral infections: development strategies and progress	76
Cancer cell therapies: the clinical trial landscape	74
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders	71
Trends in COVID-19 therapeutic clinical trials	71
Avidity in antibody effector functions and biotherapeutic drug design	69
Double setback for ASO trials in Huntington disease	68
Soluble ligands as drug targets	65
Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating	64
Immuno-oncology drug development forges on despite COVID-19	63
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment	61
Deuterium in drug discovery: progress, opportunities and challenges	60
Gene therapy community grapples with toxicity issues, as pipeline matures	60
Ligand binding at the protein–lipid interface: strategic considerations for drug design	60
Engineering islets from stem cells for advanced therapies of diabetes	60
The oncology market for antibody–drug conjugates	59
Exercise mimetics: harnessing the therapeutic effects of physical activity	58
Targeting galectin-driven regulatory circuits in cancer and fibrosis	58
AI in small-molecule drug discovery: a coming wave?	58
What does AlphaFold mean for drug discovery?	57
Clinical development times for innovative drugs	56
The glymphatic system: implications for drugs for central nervous system diseases	56
Phase 0/microdosing approaches: time for mainstream application in drug development?	55
Targeting angiogenesis in oncology, ophthalmology and beyond	54
Restoring IL-2 to its cancer immunotherapy glory	52
The expanding role for small molecules in immuno-oncology	52
Pan-coronavirus vaccine pipeline takes form	50
Strategies to access biosynthetic novelty in bacterial genomes for drug discovery	48
Addressing cancer’s grand challenges	48
Clinical trial recovery from COVID-19 disruption	47
Emerging principles of cytokine pharmacology and therapeutics	47
Landscape of cancer cell therapies: trends and real-world data	47
Applications of single-cell RNA sequencing in drug discovery and development	46
Modulating gene regulation to treat genetic disorders	46
The therapeutic potential of targeting regulated non-apoptotic cell death	46
Targeting receptor complexes: a new dimension in drug discovery	46
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems	46
Bispecific antibodies in oncology	46
Top companies and drugs by sales in 2021	44
2022 FDA approvals	43
Top companies and drugs by sales in 2020	42
Harnessing the predictive power of preclinical models for oncology drug development	42
Trends in the approval of cancer therapies by the FDA in the twenty-first century	41
Base editors hit the clinic	38
Antibody–oligonucleotide conjugates enter the clinic	37
The evolving role of investigative toxicology in the pharmaceutical industry	37
Beyond PI3Ks: targeting phosphoinositide kinases in disease	35
Thinking outside the box: non-canonical targets in multiple sclerosis	35
mRNA flu shots move into trials	35
Adoption of organ-on-chip platforms by the pharmaceutical industry	34
Digital technologies for medicines: shaping a framework for success	34
Accelerating antiviral drug discovery: lessons from COVID-19	32
Gene-editing pipeline takes off	32
VEGFA mRNA for regenerative treatment of heart failure	31
FDA approves fourth CAR-T cell therapy	31
Predictive validity in drug discovery: what it is, why it matters and how to improve it	31
Amplifying gene expression with RNA-targeted therapeutics	30
mRNA vaccines: intellectual property landscape	29
FDA approves first BCMA-targeted CAR-T cell therapy	28
Derivatization with fatty acids in peptide and protein drug discovery	26
p53 programmes plough on	26
Artificial intelligence for natural product drug discovery	25
Using human genetics to improve safety assessment of therapeutics	25
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders	25
Informing single-arm clinical trials with external controls	25
First microbiome-based drug clears phase III, in clinical trial turnaround	25
Characteristics of expedited programmes for cancer drug approval in China	24
Therapeutic RNA-silencing oligonucleotides in metabolic diseases	24

Trends in oncology drug innovation in China	24
Remote digital monitoring in clinical trials in the time of COVID-19	24
Author Correction: Targeting oxidative stress in disease: promise and limitations of antioxidant therapy	23
The clinical pipeline for cancer cell therapies	23
FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm	22
The landscape for lipid-nanoparticle-based genomic medicines	22
First de novo deuterated drug poised for approval	22
The breast cancer drug market	22
Small-molecule discovery through DNA-encoded libraries	21
Delivering on the promise of protein degraders	20
Top companies and drugs by sales in 2022	20
COVID-19 impact on oncology clinical trials: a 1-year analysis	20
The mRNA vaccine development landscape for infectious diseases	19
Evolution of the market for mRNA technology	19
AAV-based in vivo gene therapy for neurological disorders	18
HCAR3: an underexplored metabolite sensor	18
Antimalarial drug discovery: progress and approaches	18
BCKDK: an emerging kinase target for metabolic diseases and cancer	17
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies	17
Strategies to therapeutically modulate cytokine action	17
ALS antisense drug falters in phase III	16
eEF2K: an atypical kinase target for cancer	16
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections	16
Author Correction: RAS-targeted therapies: is the undruggable drugged?	16
Trends in innovative drug development in China	16
The KRAS crowd targets its next cancer mutations	15
Digital health technologies in clinical trials for central nervous system drugs: an EU regulatory perspective	15
PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders	15
FDA approves second BCMA-targeted CAR-T cell therapy	15
Implications of sex-related differences in central nervous system disorders for drug research and development	15
FDA rejects NASH drug	14
RAS-targeted therapies	14
Application of Bayesian approaches in drug development: starting a virtuous cycle	14
The market for ulcerative colitis	14
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing	14
Therapeutic approaches for Duchenne muscular dystrophy	13
Improving data sharing to increase the efficiency of antibiotic R&D	13
Type 2 chronic inflammatory diseases: targets, therapies and unmet needs	13
The prostate cancer drug market	13
Integrin-targeted therapies branch out	13
NfL makes regulatory debut as neurodegenerative disease biomarker	13
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome	13
RSV vaccines score landmark FDA approvals	12
RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape	12
Industrializing engineered autologous T cells as medicines for solid tumours	12
FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment	12
2023 FDA approvals	12
COVID-19 must catalyse changes to clinical development	12
Drug delivery systems for CRISPR-based genome editors	12
Disease modification in inflammatory skin disorders: opportunities and challenges	12
Small activating RNAs lead the charge to turn up gene expression	11
First CRISPR therapy seeks landmark approval	11
opnMe.com: a digital initiative for sharing tools with the biomedical research community	11
Targeting synapse function and loss for treatment of neurodegenerative diseases	11
FDA approves first haemophilia B gene therapy	11
Evolution of innovative drug R&D in China	11
Trispecific antibodies take to the clinic	11
Long COVID’s long R&D agenda	11
Top product forecasts for 2022	11
Author Correction: Trends in kinase drug discovery: targets, indications and inhibitor design	10
Immune status could determine efficacy of COVID-19 therapies	10
Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR	10
LAG3 pushes immuno-oncology’s leading edge	10
Comparing development strategies for PD1/PDL1-based immunotherapies	10
Kinase drug discovery 20 years after imatinib	9
Targeted protein degraders: a call for collective action to advance safety assessment	9
Orphan drug designation and development in Japan: 25 years of experience and assessment	9
Climbing cancer’s MYC mountain	9
Research on rare diseases: ten years of progress and challenges at IRDiRC	9
The failure to fail smartly	9
CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancers	9
Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections	9
Transferrin’ across the blood–brain barrier	8
LRRK2-targeted Parkinson disease drug advances into phase III	8
Accelerating therapeutic discoveries for heart failure: a new public–private partnership	8
T cell receptor therapeutics hit the immuno-oncology stage	8
Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor	8
Fragment-based screening sees the light	8
FDA approves AstraZeneca’s anifrolumab for lupus	8
The R&D landscape for infectious disease vaccines	8
Novel drug targets in 2021	7
Author Correction: mRNA vaccines for infectious diseases: principles, delivery and clinical translation	7
What’s next for the synthetic lethality drug discovery engine?	7
FDA approves first all-oral sleeping sickness drug	7
Strategies to reduce the risks of mRNA drug and vaccine toxicity	7
The most successful oncology drug portfolios of the past decade	7
The next-generation CAR-T therapy landscape	7
‘Bespoke Gene Therapy Consortium’ sets out to enable gene therapies for ultra-rare diseases	7
Proximity-inducing drugs get closer	7
FDA approves antibody cocktail for Ebola virus	7
Anti-tau antibody failures stack up	7
Trends in the use of liquid biopsy in oncology	7
Translational misconceptions	7
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets	7
Targeting the mitochondria to block tumour growth	7